Cargando…

Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study

Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6−IL-17 axis and IL-12−IFN-γ axis play critical roles in the disease development. We aimed to clarify the association between...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Nobuya, Kono, Michihiro, Kono, Michihito, Katsuyama, Takayuki, Ohmura, Kazumasa, Sato, Taiki, Karino, Kohei, Fujieda, Yuichiro, Kato, Masaru, Hasebe, Rie, Murakami, Masaaki, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727250/
https://www.ncbi.nlm.nih.gov/pubmed/36505494
http://dx.doi.org/10.3389/fimmu.2022.1066916
_version_ 1784844971539431424
author Abe, Nobuya
Kono, Michihiro
Kono, Michihito
Katsuyama, Takayuki
Ohmura, Kazumasa
Sato, Taiki
Karino, Kohei
Fujieda, Yuichiro
Kato, Masaru
Hasebe, Rie
Murakami, Masaaki
Atsumi, Tatsuya
author_facet Abe, Nobuya
Kono, Michihiro
Kono, Michihito
Katsuyama, Takayuki
Ohmura, Kazumasa
Sato, Taiki
Karino, Kohei
Fujieda, Yuichiro
Kato, Masaru
Hasebe, Rie
Murakami, Masaaki
Atsumi, Tatsuya
author_sort Abe, Nobuya
collection PubMed
description Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6−IL-17 axis and IL-12−IFN-γ axis play critical roles in the disease development. We aimed to clarify the association between the disease state and cytokine/chemokine levels, to assess disease course as prognosis and to predict regulators in patients with LVV using the blood profiles of multiple cytokines/chemokines. This retrospective analysis comprised 35 LVV patients whose blood were collected, and multiplex cytokine/chemokine analysis with 28 analytes was performed. The differences of cytokines/chemokines corresponding disease status, upstream regulator analysis, pathway analysis and cluster analysis were conducted using the cytokines/chemokines profile. Relapse-free survival rate was calculated with Kaplan-Meier analysis in the classified clusters. In the robust analysis, IL-4, CCL2/MCP-1, TNFSF13/APRIL, TNFSF13B/BAFF, CHI3L1 and VEGF-A levels were significantly changed after treatment. Untreated LVV patients demonstrated activation of NFκB-related molecules and these patients are potentially treated with JAK/STAT inhibitors, anti-TNF-α inhibitors and IL-6 inhibitors. Cluster analysis in active LVV patients revealed two clusters including one with high blood levels of IL-1β, IL-6, IL-17, IL-23 and CCL20/MIP-3. A subgroup of the LVV patients showed activated IL-17 signature with high relapse frequency, and JAK/TyK2 inhibitors and IFN-γ inhibitors were detected as potentially upstream inhibitors. Blood cytokine/chemokine profiles would be useful for prediction of relapse and potentially contributes to establish therapeutic strategy as precision medicine in LVV patients.
format Online
Article
Text
id pubmed-9727250
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97272502022-12-08 Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study Abe, Nobuya Kono, Michihiro Kono, Michihito Katsuyama, Takayuki Ohmura, Kazumasa Sato, Taiki Karino, Kohei Fujieda, Yuichiro Kato, Masaru Hasebe, Rie Murakami, Masaaki Atsumi, Tatsuya Front Immunol Immunology Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6−IL-17 axis and IL-12−IFN-γ axis play critical roles in the disease development. We aimed to clarify the association between the disease state and cytokine/chemokine levels, to assess disease course as prognosis and to predict regulators in patients with LVV using the blood profiles of multiple cytokines/chemokines. This retrospective analysis comprised 35 LVV patients whose blood were collected, and multiplex cytokine/chemokine analysis with 28 analytes was performed. The differences of cytokines/chemokines corresponding disease status, upstream regulator analysis, pathway analysis and cluster analysis were conducted using the cytokines/chemokines profile. Relapse-free survival rate was calculated with Kaplan-Meier analysis in the classified clusters. In the robust analysis, IL-4, CCL2/MCP-1, TNFSF13/APRIL, TNFSF13B/BAFF, CHI3L1 and VEGF-A levels were significantly changed after treatment. Untreated LVV patients demonstrated activation of NFκB-related molecules and these patients are potentially treated with JAK/STAT inhibitors, anti-TNF-α inhibitors and IL-6 inhibitors. Cluster analysis in active LVV patients revealed two clusters including one with high blood levels of IL-1β, IL-6, IL-17, IL-23 and CCL20/MIP-3. A subgroup of the LVV patients showed activated IL-17 signature with high relapse frequency, and JAK/TyK2 inhibitors and IFN-γ inhibitors were detected as potentially upstream inhibitors. Blood cytokine/chemokine profiles would be useful for prediction of relapse and potentially contributes to establish therapeutic strategy as precision medicine in LVV patients. Frontiers Media S.A. 2022-11-23 /pmc/articles/PMC9727250/ /pubmed/36505494 http://dx.doi.org/10.3389/fimmu.2022.1066916 Text en Copyright © 2022 Abe, Kono, Kono, Katsuyama, Ohmura, Sato, Karino, Fujieda, Kato, Hasebe, Murakami and Atsumi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Abe, Nobuya
Kono, Michihiro
Kono, Michihito
Katsuyama, Takayuki
Ohmura, Kazumasa
Sato, Taiki
Karino, Kohei
Fujieda, Yuichiro
Kato, Masaru
Hasebe, Rie
Murakami, Masaaki
Atsumi, Tatsuya
Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
title Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
title_full Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
title_fullStr Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
title_full_unstemmed Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
title_short Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
title_sort cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: a preliminary observational study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727250/
https://www.ncbi.nlm.nih.gov/pubmed/36505494
http://dx.doi.org/10.3389/fimmu.2022.1066916
work_keys_str_mv AT abenobuya cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT konomichihiro cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT konomichihito cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT katsuyamatakayuki cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT ohmurakazumasa cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT satotaiki cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT karinokohei cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT fujiedayuichiro cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT katomasaru cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT haseberie cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT murakamimasaaki cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy
AT atsumitatsuya cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy